mitomycin
Trade name: mutamycin
Approved
Jun 1, 1973
The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour activity. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to reduce fibrosis in strabismus surgery. The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue. Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'. Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation. Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery. — NCATS
Clinical trial activity
231 trials · 261 clinical orgs · 18 marketing orgs
Earliest trial started Sep 1, 1991 (NCT00002490)
Timeline
1970s
- Jun 1, 1973
Earliest FDA Approval
- Jun 1, 1974
Bristol-Myers — First NDA Organization
- Jun 1, 1974
Bristol-Myers — NDA Organization
1980s
- Aug 24, 1981
Bristol-Myers Squibb — Marketing Organization
1990s
- Jan 1, 1991
Earliest Phase 3 Sponsor(trial)
- Jan 1, 1994
Earliest Phase 2 Sponsor(trial)
- Apr 19, 1995
West-Ward Pharmaceutical — Marketing Organization
- Apr 19, 1995
Hikma — Marketing Organization
- Nov 29, 1995
Hospira — Marketing Organization
- Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
- Apr 30, 1998
Accord Research — Marketing Organization
2000s
- Nov 14, 2002
SuperGen — NDA Secondary Org
2010s
- Feb 7, 2012
Mobius Therapeutics — NDA Secondary Org
- Feb 7, 2012
Glaukos Corporation — Marketing Organization
- Oct 13, 2017
Mylan — Marketing Organization
- Oct 13, 2017
Apicore — Marketing Organization
2020s
- Apr 15, 2020
UroGen Pharma — Marketing Organization
- Apr 15, 2020
UroGen Pharma — NDA Secondary Org
- Oct 20, 2021
Gland Pharma Ltd — Marketing Organization
- Oct 20, 2021
Fosun — Marketing Organization
- Sep 6, 2022
Eu Yan Sang — Marketing Organization
- Sep 6, 2022
Meitheal — Marketing Organization
- Oct 30, 2023
Eugia Pharma — Marketing Organization
- Apr 5, 2024
Fresenius — Marketing Organization
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 2
- Anastomotic Leak · Phase 2
- Angiography · Early Phase 1
- Anus Diseases · Phase 3
- Anus Neoplasms · Phase 3
- Appendiceal Neoplasms · Phase 2
- Appendix · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Breast Neoplasms · Phase 3
- Carcinoma · Phase 3
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma in Situ · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Ovarian Epithelial · Phase 2
- Carcinoma, Renal Cell · Phase 3
- Carcinoma, Squamous Cell · Phase 3
- Carcinoma, Transitional Cell · Phase 3
- Cataract · Phase 2
- Cholangiocarcinoma · Phase 2
- Cholangitis, Sclerosing · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 3
- Conjunctival Neoplasms · Phase 4
- Corneal Diseases · Phase 4
- Corneal Opacity · Phase 2/Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Esophageal Neoplasms · Phase 2
- Esophageal Stenosis · Phase 2
- Esophagogastric Junction · Phase 2
- Eye Diseases · Early Phase 1
- Fallopian Tube Neoplasms · Phase 2
- Gallbladder Neoplasms · Phase 1/Phase 2
- Gastrointestinal Neoplasms · Phase 2
- General Surgery · Phase 2
- Glaucoma, Angle-Closure · Phase 3
- Glaucoma, Neovascular · Phase 3
- Glaucoma, Open-Angle · Phase 4
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 4
- HIV Infections · Phase 2
- Intestinal Neoplasms · Phase 1
- Keratoconus · Phase 2
- Leukemia · Phase 1
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 3
- Mediastinal Neoplasms · Phase 2
- Mesothelioma, Malignant · Phase 3
- Mycobacterium · Phase 3
- Myopia · Phase 4
- Nasal Cavity · Phase 2
- Nasopharyngeal Carcinoma · Phase 3
- Neoplasm Metastasis · Phase 3
- Neoplasm Recurrence, Local · Phase 3
- Neoplasms by Site · Phase 3
- Neoplasms, Squamous Cell · Phase 3
- Neuroendocrine Tumors · Phase 3
- Optic Nerve · Early Phase 1
- Oropharyngeal Neoplasms · Phase 4
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 3
- Pediatrics · Phase 3
- Peritoneal Neoplasms · Phase 3
- Pleural Neoplasms · Phase 2
- Postoperative Complications · Phase 3
- Presbyopia · Phase 4
- Pseudomyxoma Peritonei · Phase 3
- Pterygium · Phase 4
- Rectal Neoplasms · Phase 3
- Refractive Errors · Phase 4
- Risk · Phase 2
- Sarcoma · Phase 2
- Sinusitis · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Diseases · Phase 1
- Stomach Neoplasms · Phase 3
- Survival · Phase 2
- Tissue Adhesions · Phase 2
- Trabeculectomy · Phase 3
- Ureteral Neoplasms · Phase 2
- Urethral Diseases · Phase 3
- Urethral Neoplasms · Phase 2
- Urethral Stricture · Phase 2/Phase 3
- Urinary Bladder Diseases · Phase 3
- Urinary Bladder Neoplasms · Phase 4
- Urogenital Neoplasms · Phase 3
- Urologic Diseases · Phase 3
- Urologic Neoplasms · Phase 3
- Uterine Cervical Neoplasms · Phase 3
- Uveitis · Phase 3
- Wound Healing · Phase 2
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Approval history
- approvedJun 1, 1973
Chemistry & pharmacology
SMILES
CO[C@]12[C@H]3N[C@H]3CN1C4=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C4=O- Mol. weight
- 334.3272 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- WikipediaMitomycins ↗
- NCATS50SG953SK6 ↗
- ChEMBLCHEMBL105 ↗
Also known as
- 7-amino-9alpha-methoxymitosane
- 7-amino-9alpha-methoxymitosane
- ametycine
- ametycine
- mitamycin
- mitamycin
- mitocin-c
- mitocin-c
- mitogel
- mitomycin
- mitomycin
- mitomycin
- mitomycin
- mitomycin
- mitomycin
- mitomycin
- mitomycin
- mitomycin
- mitomycin
- mitomycin
- mitomycin c
- mitomycin c
- mitomycin c
- mitomycin c
- mitomycin c
- mitomycin-c
- mitomycin-c
- mitosol
- mitosol
- mitozytrex
- mitozytrex
- mmc
- mmc
- mutamycin
- mutamycin
- mutamycin
- mutamycin
- mytozytrex
- mytozytrex
- nsc-26980
- nsc-26980
- promitil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07271355 | Phase 3 | Jul 1, 2026 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT06783491 | Phase 3 | Dec 31, 2025 | Spanish Association of Surgeons (AEC), Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Universidad de Cordoba |
| NCT07189793 | Phase 2 | Oct 31, 2025 | Wenzhou Medical University |
| NCT06919965 | Phase 3 | Sep 10, 2025 | — |
| NCT07097142 | Phase 3 | Aug 14, 2025 | NRG Oncology |
| NCT06774131 | Phase 3 | May 2, 2025 | UroGen Pharma |
| NCT06770582 | Phase 2 | Mar 7, 2025 | National Cancer Institute (NCI), NRG Oncology |
| NCT06781879 | Phase 4 | Feb 24, 2025 | Aarhus University, Danish Cancer Society, Medac |
| NCT06704191 | Phase 1/Phase 2 (Phase 2) | Dec 6, 2024 | Mayo Clinic, National Center for Advancing Translational Science (NCATS) |
| NCT06680245 | Phase 3 | Dec 1, 2024 | University of Western Ontario |
| NCT06696794 | Phase 3 | Dec 1, 2024 | Huazhong University of Science and Technology |
| NCT06227065 | Phase 2 | Oct 31, 2024 | University of Bern |
| NCT06513065 | Phase 3 | Sep 30, 2024 | Moorgreen Hospital, Southampton |
| NCT06331299 | Phase 3 | Aug 29, 2024 | UroGen Pharma |
| NCT06478862 | Phase 2 | Jun 13, 2024 | Ben Gurion University, Hebrew University, Lipomedix Pharmaceuticals Inc., Technion University, Tel Aviv University |
| NCT06319820 | Phase 3 | Apr 18, 2024 | Johnson and Johnson |
| NCT06211764 | Phase 3 | Apr 9, 2024 | — |
| NCT06944132 | N/A | Apr 1, 2024 | Benha University |
| NCT06233877 | Phase 2 | Mar 15, 2024 | Hirschfeld Oncology |
| NCT05979909 | Phase 1 | Sep 30, 2023 | McMaster University |
Organizations
Research & Development (261)
Marketing (20)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Accord Research | For profit | MKTG | Apr 30, 1998 |
| Apicore | For profit | MKTG | Oct 13, 2017 |
| Bristol-Myers | For profit | NDA | Jun 1, 1974 |
| Bristol-Myers Squibb | For profit | MKTG | Aug 24, 1981 |
| Eu Yan Sang | For profit | MKTG | Sep 6, 2022 |
| Eugia Pharma | For profit | MKTG | Oct 30, 2023 |
| Fosun | For profit | MKTG | Oct 20, 2021 |
| Fresenius | For profit | MKTG | Apr 5, 2024 |
| Gland Pharma Ltd | For profit | MKTG | Oct 20, 2021 |
| Gland Pharma Ltd | For profit | SYN | Oct 20, 2021 |
| Glaukos Corporation | For profit | MKTG | Feb 7, 2012 |
| Hikma | For profit | MKTG | Apr 19, 1995 |
| Hospira | For profit | MKTG | Nov 29, 1995 |
| Meitheal | For profit | MKTG | Sep 6, 2022 |
| Mobius Therapeutics | For profit | NDA2 | Feb 7, 2012 |
| Mylan | For profit | MKTG | Oct 13, 2017 |
| SuperGen | For profit | NDA2 | Nov 14, 2002 |
| UroGen Pharma | For profit | MKTG | Apr 15, 2020 |
| UroGen Pharma | For profit | NDA2 | Apr 15, 2020 |
| West-Ward Pharmaceutical | For profit | MKTG | Apr 19, 1995 |